Innova Captab

Innova Captab

751.30
+21.20
(2.90%)
ann
Company has added their latest Transcript1 day ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
Market Cap
4,178.00 Cr
EPS
22.41
PE Ratio
34.56
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,260.00
52 Week Low
662.00
PB Ratio
4.21
Debt to Equity
0.33
Analyst Rating and Forecast
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Innova Captab Reports 19.5% Revenue Growth Despite API Price Decline Challenges1 day ago
Innova Captab Limited achieved consolidated revenue of INR 380.4 crores in Q2 FY26 and INR 731.9 crores in H1 FY26, marking 19.5% year-on-year growth despite declining API prices impacting their CDMO business. The company's Jammu facility received regulatory approvals from UK-MHRA and Ukraine's SMDC, with management revising annual guidance from INR 400 crores to INR 270-280 crores due to GST rate reduction from 12% to 5%.
positive
Innova Captab has outlined its growth strategy targeting 25% revenue growth through CDMO expansion and entry into regulated markets. The company plans to invest ₹300 crores in capital expenditure for capacity addition and research & development. Key focus areas include strengthening backward integration for APIs, scaling formulation exports, and expanding its oncology portfolio. The company aims to enhance margins through vertical integration and global partnerships.
neutral
Innova Captab Reports Mixed Q2 Results with Revenue Growth but Lower Profit Margins7 days ago
Innova Captab reported quarterly results showing revenue growth to 3.8 billion rupees from 3.2 billion rupees year-over-year. EBITDA increased to 518 million rupees from 498 million rupees, though EBITDA margin declined to 13.62% from 15.63%. Consolidated net profit decreased to 297 million rupees compared to 350 million rupees in the same period last year.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,757.10
#1 4,16,860.50
40.19
#1 54,729.00
9.71
#1 10,980
2.89
71.24
6,511.50
1,75,036.70
69.56
9,712.00
18.67
2,191
35.10
49.85
3,831.80
1,29,492.60
60.73
11,539.40
6.99
1,911
30.46
70.96
1,532.10
1,23,247.10
22.77
28,409.50
7.12
5,291
3.71
48.07
1,246.00
1,03,066.50
#1 18.11
33,741.20
16.73
5,725
-0.38
52.75
944.45
95,003.60
18.89
23,511.00
18.55
4,615
34.60
37.46
2,055.30
93,767.10
21.59
22,909.50
13.74
3,306
#1 72.75
65.62
2,267.10
93,159.60
52.74
12,744.20
#1 20.90
2,007
-21.05
33.43
1,222.50
70,288.60
20.93
32,345.60
9.43
3,484
3.81
73.28
5,722.50
68,456.90
28.40
13,458.30
3.70
2,216
10.98
64.53

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
14.80 %
Net Income Growth
36.06 %
Cash Flow Change
-56.38 %
ROE
17.80 %
ROCE
-1.26 %
EBITDA Margin (Avg.)
3.41 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
217
244
245
244
234
286
305
268
296
320
321
318
356
385
Expenses
197
211
208
214
202
243
258
225
252
269
270
267
299
329
EBITDA
21
33
37
29
32
44
47
44
44
52
51
51
57
56
Operating Profit %
9 %
13 %
14 %
11 %
13 %
14 %
15 %
15 %
14 %
16 %
15 %
15 %
15 %
14 %
Depreciation
3
3
3
3
3
5
5
3
5
5
5
10
11
11
Interest
3
5
6
5
5
9
7
1
0
0
0
2
3
6
Profit Before Tax
15
25
28
21
25
30
35
40
39
47
46
39
43
39
Tax
2
6
9
4
7
7
10
11
10
12
11
10
12
10
Net Profit
13
19
20
17
18
23
25
29
30
35
34
30
31
30
EPS in ₹
108.91
3.91
4.08
3.59
3.67
4.77
4.39
5.02
5.15
6.12
5.97
5.17
5.42
5.18

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
2025
Total Assets
0
245
370
576
704
1,321
1,580
Fixed Assets
0
73
79
183
183
358
830
Current Assets
0
171
271
379
443
580
696
Capital Work in Progress
0
0
7
0
22
341
23
Investments
0
0
0
0
0
0
0
Other Assets
0
172
283
392
500
622
728
Total Liabilities
0
245
370
576
704
1,321
1,580
Current Liabilities
0
120
215
295
278
266
353
Non Current Liabilities
0
14
10
72
150
225
268
Total Equity
0
110
145
209
277
831
959
Reserve & Surplus
0
98
133
197
229
774
902
Share Capital
0
12
12
12
48
57
57

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
1
2
3
-5
3
8
4
Investing Activities
-9
-6
-20
-188
-91
-499
-152
Operating Activities
19
31
42
59
67
146
64
Financing Activities
-9
-23
-19
125
27
361
92

Share Holding

% Holding
Jun 2022
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
69.75 %
50.90 %
50.90 %
50.90 %
50.90 %
50.90 %
50.90 %
50.90 %
50.90 %
50.90 %
FIIs
0.00 %
0.00 %
0.00 %
1.94 %
1.19 %
1.01 %
0.74 %
0.34 %
0.23 %
0.08 %
DIIs
0.00 %
11.73 %
4.98 %
20.77 %
21.23 %
20.61 %
19.96 %
19.76 %
19.67 %
20.17 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
32.10 %
32.29 %
25.47 %
25.80 %
26.00 %
26.96 %
27.62 %
27.71 %
27.35 %
Others
30.25 %
5.26 %
11.83 %
0.91 %
0.88 %
1.48 %
1.45 %
1.37 %
1.49 %
1.50 %
No of Share Holders
7
1,39,154
1,39,154
39,396
35,115
32,254
36,692
39,996
41,014
40,245

Announcements

Announcement under Regulation 30 (LODR)-Earnings Call Transcript1 day ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome4 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation7 days ago
Approval Of The Unaudited (Standalone And Consolidated) Financial Results For The Quarter And Half Year Ended 30Th September 2025.7 days ago
Mr. Devendra Ganpatrav Palav Who Currently Serves As The Chief Executive Officer (CEO) Of Sharon Bio-Medicine Limited A Material Subsidiary Of The Company Has Been Redesignated As Manager In Addition To His Existing Role As CEO.7 days ago
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. 07Th November 20257 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 03, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (LODR)Regulations 2015 For Consideration Of Unaudited (Standalone And Consolidated) Financial Results For The Quarter And Half Year Ended 30Th September 2025.Oct 30, 2025
Recommendation Of GMP Compliance Certificate By The State Service Of Ukraine On Medicines And Drugs Control.Oct 20, 2025
Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.Oct 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Closure of Trading WindowSep 26, 2025
Pursuant To Regulation 30 Read With Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) We Hereby Inform You That M/S. CARE Ratings Limited A Credit Rating Agency Has Revised The CreSep 16, 2025
Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (The Listing Regulations).Aug 21, 2025
Pursuant To The Regulation 30 (Read With Part A Of Schedule III) And Other Applicable Provisions Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) We Hereby Inform That The Company Has Successfully Completed Aug 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Outcome Of The Board Meeting Held Today I.E. 07Th August 2025Aug 07, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. 07Th August 2025Aug 07, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 31, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMJul 31, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For Consideration Of Unaudited (Standalone And Consolidated) Financial Results For The Quarter EndJul 30, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJul 25, 2025
Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations 2011Jul 09, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 05, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 04, 2025
Reg. 34 (1) Annual Report.Jul 04, 2025
The 21St Annual General Meeting (AGM) Of The Members Of Innova Captab Limited Will Be Held On Thursday 31St July 2025 At 11:00 A.M. (IST) Through Video Conferencing/Other Audio Visual Means (VC/OAVM) In Accordance With The Relevant Circulars Issued By MinJul 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025
Closure of Trading WindowJun 25, 2025
Gift Of SharesJun 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2025
Shifting Of Registered OfficeMay 19, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 19, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. 19Th May 2025May 19, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For Consideration Of Audited Financial Results For The Quarter And Year Ended March 31 2025.May 12, 2025

Technical Indicators

RSI(14)
Neutral
31.85
ATR(14)
Volatile
27.30
STOCH(9,6)
Oversold
8.38
STOCH RSI(14)
Oversold
9.46
MACD(12,26)
Bearish
-9.12
ADX(14)
Weak Trend
19.08
UO(9)
Bearish
30.63
ROC(12)
Downtrend And Accelerating
-9.11
WillR(14)
Oversold
-81.28